Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MBRX NASDAQ:PMN NASDAQ:RLYB NASDAQ:XBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMBRXMoleculin Biotech$0.48-4.7%$0.48$0.25▼$3.65$24.98M1.592.55 million shs1.49 million shsPMNPromis Neurosciences$0.44-2.1%$0.49$0.38▼$1.59$24.21M-0.17881,136 shs546,517 shsRLYBRallybio$0.56+1.5%$0.57$0.22▼$1.24$23.06M-1.1320,444 shs160,251 shsXBIOXenetic Biosciences$3.87-5.6%$3.64$2.20▼$13.93$6.32M2.422.54 million shs153,765 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMBRXMoleculin Biotech-4.68%-2.83%+19.44%-32.15%-81.99%PMNPromis Neurosciences-2.13%-4.07%-0.27%-49.96%-53.65%RLYBRallybio+1.47%+4.71%-4.86%+5.86%-49.09%XBIOXenetic Biosciences-5.61%-23.67%+23.64%+6.61%+2.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMBRXMoleculin Biotech$0.48-4.7%$0.48$0.25▼$3.65$24.98M1.592.55 million shs1.49 million shsPMNPromis Neurosciences$0.44-2.1%$0.49$0.38▼$1.59$24.21M-0.17881,136 shs546,517 shsRLYBRallybio$0.56+1.5%$0.57$0.22▼$1.24$23.06M-1.1320,444 shs160,251 shsXBIOXenetic Biosciences$3.87-5.6%$3.64$2.20▼$13.93$6.32M2.422.54 million shs153,765 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMBRXMoleculin Biotech-4.68%-2.83%+19.44%-32.15%-81.99%PMNPromis Neurosciences-2.13%-4.07%-0.27%-49.96%-53.65%RLYBRallybio+1.47%+4.71%-4.86%+5.86%-49.09%XBIOXenetic Biosciences-5.61%-23.67%+23.64%+6.61%+2.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMBRXMoleculin Biotech 2.33Hold$4.00731.60% UpsidePMNPromis Neurosciences 2.50Moderate Buy$4.33884.18% UpsideRLYBRallybio 1.80Reduce$5.00792.86% UpsideXBIOXenetic Biosciences 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest XBIO, MBRX, PMN, and RLYB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025MBRXMoleculin BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025PMNPromis NeurosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025RLYBRallybioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025XBIOXenetic BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MBRXMoleculin BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025PMNPromis NeurosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025RLYBRallybioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025XBIOXenetic BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/10/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.008/27/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.00(Data available from 10/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMBRXMoleculin BiotechN/AN/AN/AN/A$1.77 per shareN/APMNPromis NeurosciencesN/AN/AN/AN/A$0.50 per shareN/ARLYBRallybio$640K36.57N/AN/A$1.49 per share0.38XBIOXenetic Biosciences$2.45M2.44N/AN/A$3.89 per share0.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMBRXMoleculin Biotech-$21.76MN/A0.00N/AN/AN/A-1,498.41%-114.47%11/14/2025 (Estimated)PMNPromis Neurosciences$2.78M-$0.21N/AN/AN/AN/A-266.69%-131.59%11/13/2025 (Estimated)RLYBRallybio-$57.78M-$0.94N/AN/AN/A-5,473.33%-71.66%-65.06%11/6/2025 (Estimated)XBIOXenetic Biosciences-$3.96M-$2.00N/AN/AN/A-126.08%-54.56%-47.28%11/11/2025 (Estimated)Latest XBIO, MBRX, PMN, and RLYB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/14/2025Q3 2025MBRXMoleculin Biotech-$0.20N/AN/AN/AN/AN/A11/13/2025Q3 2025PMNPromis Neurosciences-$0.15N/AN/AN/AN/AN/A11/11/2025Q3 2025XBIOXenetic Biosciences-$0.49N/AN/AN/AN/AN/A11/6/2025Q3 2025RLYBRallybio-$0.25N/AN/AN/AN/AN/A8/13/2025Q2 2025PMNPromis Neurosciences-$0.22-$0.29-$0.07-$0.29N/AN/A8/12/2025Q2 2025MBRXMoleculin Biotech-$0.39-$0.49-$0.10-$0.49N/AN/A8/12/2025Q2 2025XBIOXenetic Biosciences-$0.64-$0.45+$0.19-$0.45$0.48 million$0.59 million8/7/2025Q2 2025RLYBRallybio-$0.2450-$0.22+$0.0250-$0.22N/A$0.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMBRXMoleculin BiotechN/AN/AN/AN/AN/APMNPromis NeurosciencesN/AN/AN/AN/AN/ARLYBRallybioN/AN/AN/AN/AN/AXBIOXenetic BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMBRXMoleculin BiotechN/A1.151.15PMNPromis NeurosciencesN/A0.970.97RLYBRallybioN/A9.989.98XBIOXenetic BiosciencesN/A5.935.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMBRXMoleculin Biotech15.52%PMNPromis Neurosciences50.13%RLYBRallybio90.34%XBIOXenetic Biosciences15.12%Insider OwnershipCompanyInsider OwnershipMBRXMoleculin Biotech3.40%PMNPromis Neurosciences3.80%RLYBRallybio8.70%XBIOXenetic Biosciences14.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMBRXMoleculin Biotech2049.50 million47.82 millionNot OptionablePMNPromis Neurosciences553.81 million51.77 millionNot OptionableRLYBRallybio4041.79 million38.15 millionNot OptionableXBIOXenetic Biosciences41.54 million1.32 millionNot OptionableXBIO, MBRX, PMN, and RLYB HeadlinesRecent News About These CompaniesXenetic Biosciences Announces Public Offering PricingOctober 14, 2025 | msn.comXenetic 735,000 share Spot Secondary priced at $6.12October 10, 2025 | msn.comMicron, Galecto And Xenetic Lead This Week's Benzinga Stock Ranking SurgesOctober 10, 2025 | benzinga.comXenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common StockOctober 10, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Reports Second Quarter 2025 Financial ResultsAugust 13, 2025 | accessnewswire.comAXenetic Biosciences Reports Improved Financial PerformanceAugust 13, 2025 | msn.comXenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue EstimatesAugust 12, 2025 | zacks.comXenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell LymphomaJuly 30, 2025 | accessnewswire.comAXenetic Biosciences expands R&D collaboration with The Scripps Research Institute to advance DNase platformJuly 26, 2025 | pharmabiz.comPXenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase PlatformJuly 23, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the ...July 8, 2025 | finanznachrichten.deXenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic CancerJuly 8, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | accessnewswire.comAXenetic Biosciences (XBIO) Receives a Hold from H.C. WainwrightApril 9, 2025 | markets.businessinsider.comXenetic Biosciences, Inc. Releases Virtual Investor "What This Means" SegmentApril 9, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Releases Virtual Investor "What This Means" SegmentApril 9, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing SarcomaMarch 26, 2025 | accessnewswire.comAXenetic Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS LagsMarch 20, 2025 | finance.yahoo.comXenetic Biosciences, Inc. Reports Full Year 2024 Financial ResultsMarch 19, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic ResponsesMarch 13, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeXBIO, MBRX, PMN, and RLYB Company DescriptionsMoleculin Biotech NASDAQ:MBRX$0.48 -0.02 (-4.68%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$0.45 -0.03 (-7.07%) As of 05:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.Promis Neurosciences NASDAQ:PMN$0.44 -0.01 (-2.13%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$0.45 +0.01 (+1.75%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Rallybio NASDAQ:RLYB$0.56 +0.01 (+1.47%) Closing price 10/21/2025 03:59 PM EasternExtended Trading$0.55 -0.01 (-1.25%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.Xenetic Biosciences NASDAQ:XBIO$3.87 -0.23 (-5.61%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$3.88 +0.01 (+0.26%) As of 05:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
